ProHeart 12 is FDA-approved and considered safe for healthy dogs 12 months of age and older. The FDA evaluated safety in 404 animals before approval, including 297 client-owned dogs, and also reviewed nearly two decades of real-world data from Australia, where the product has been on the market since 2000. Most dogs tolerate the injection well, but there are specific risks worth understanding before your dog gets the shot.
How ProHeart 12 Works
ProHeart 12 is an injectable heartworm preventive that releases its active ingredient, moxidectin, slowly over 12 months. It uses the same formulation as ProHeart 6 (the six-month version) but at three times the concentration, which extends protection to a full year. Because it’s given as a single injection at the vet’s office, it eliminates the risk of missed monthly doses, which is the most common reason heartworm prevention fails.
Common Side Effects
In the FDA’s field study, the most frequently reported side effects were vomiting, diarrhea, and decreased appetite. These occurred at roughly the same rate in dogs that received ProHeart 12 and dogs in the control group, meaning they may not have been caused by the drug itself. When appetite loss did occur, it was generally mild, short-lived, and resolved on its own before the study ended.
Injection site reactions are also possible. In safety testing, some dogs developed swelling and thickening at the injection site, but these weren’t associated with pain or other clinical problems.
Rare but Serious Reactions
The more concerning risks are uncommon allergic reactions. In the pre-approval study, two dogs experienced mild to moderate hypersensitivity reactions within 24 hours of their first injection. Both recovered fully, and neither dog reacted when they received a second dose a year later.
One dog in the field study had a severe seizure 19 days after treatment and required medical intervention. The earlier ProHeart 6 formulation had its own rocky history: it was voluntarily recalled in 2004 after reports of anaphylaxis, liver disease, autoimmune blood disorders, seizures, and death. The FDA ultimately allowed ProHeart 6 back on the market with additional safety requirements, and ProHeart 12 now falls under the same risk management program. Veterinarians must complete a certification training that covers recognizing and managing immune reactions, including anaphylaxis, before they can administer either product.
This certification requirement is unusual for a veterinary drug and reflects the FDA’s acknowledgment that while serious reactions are rare, they can be severe when they do occur. Your vet’s office should be prepared to monitor your dog for at least 15 to 30 minutes after the injection.
Safety in Sensitive Breeds
Breeds like Collies, Australian Shepherds, and Shelties sometimes carry a genetic mutation (called MDR1) that makes them dangerously sensitive to certain parasite medications. This is a legitimate concern with any drug in moxidectin’s class, but ProHeart 12 has been specifically tested in ivermectin-sensitive Collies at up to five times the recommended dose. No adverse reactions were observed. The FDA has determined the product is safe for dogs with the MDR1 mutation when used at label doses.
Dogs That Should Not Get ProHeart 12
ProHeart 12 is only approved for dogs 12 months and older. It has not been evaluated in puppies younger than that. The label also specifically states it should not be given to dogs that are sick, debilitated, underweight, or have a history of weight loss. Only healthy dogs should receive the injection.
Dogs must be tested for existing heartworm infection before getting the shot. ProHeart 12 prevents new infections but does not kill adult heartworms. Giving it to a dog that’s already infected can cause serious problems. In lab studies, dogs with younger (four-month-old) heartworm infections that received moxidectin experienced vomiting, lethargy, and bloody diarrhea, with one dog becoming so ill it needed supportive care. Dogs with older infections tolerated it better, and dogs with only adult heartworms given three times the label dose showed no adverse effects, but the risk is real enough that any existing infection should be treated first.
Safety at Higher Doses
The FDA’s margin of safety study gave Beagles repeated injections at up to five times the recommended dose on days 1, 183, and 365. The drug was well tolerated at all dose levels, with no systemic adverse effects. The only finding was injection site swelling, which didn’t cause clinical problems. Reproductive safety testing at three times the normal dose showed no effects on conception, pregnancy, puppy development, or male fertility.
How It Compares to Monthly Preventives
Every heartworm preventive carries some risk of side effects, whether it’s a monthly chewable, topical, or injectable. ProHeart 12’s advantage is eliminating the possibility of gaps in coverage from forgotten or late doses. Its disadvantage is that once injected, the drug can’t be removed if your dog has a bad reaction. With a monthly pill or topical, you simply stop giving it. With ProHeart 12, the moxidectin continues releasing for the full 12 months. This is worth weighing if your dog has a history of drug sensitivities or immune-mediated conditions.
For most healthy adult dogs, ProHeart 12 has a well-supported safety profile backed by extensive pre-approval testing and years of international use. The serious reactions that led to ProHeart 6’s recall in 2004 prompted meaningful changes in how the product is administered, including mandatory veterinary certification and closer post-injection monitoring. Those safeguards now apply to ProHeart 12 as well.